Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Degludec Advisory Committee Is Another De Facto Delay For Novo

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.


Related Content

Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety
Investors Optimistic On FDA Panel For Novo’s Insulin Degludec
Contract Research Firm CMIC Joins Pharma Market With One Orphan Drug And More On The Way
Contract Research Firm CMIC Joins Pharma Market With Orphan Drug, With More On The Way
Beyond Victoza: Novo Nordisk Sheds Light On GLP-1/Insulin Product
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
More Insulin Innovation To Come, Says Novo CEO Sorensen
Pricing Under The Spotlight As Novo Files Next-Generation Insulins
Sanofi Counts FDA As New Supporter In Lantus Cancer Scare


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts